Roche pushes a novel myeloma target
The company will be the first to take a FcRH5-targeting project into phase 3.
Roche sets up a breast cancer déjà vu
Like Orserdu, giredestrant works in all-comers in an ESR1m-enriched trial.
What now for NK-cell engagers?
Big pharma interest remains, but the mood is fast turning gloomy.
Kura harks back to its roots
After menin, the company tries again with farnesyl transferase.
